We expect investors to focus on Viking Therapeutics’ VKTX progress with the development of its lead candidate, VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results